New Two-Drug attack on Hard-to-Treat myeloma enters early human tests

NCT ID NCT07280013

Recruiting now Disease control Sponsor: C4 Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers will also check whether the drugs shrink tumors. Participants will take cemsidomide for two weeks on and two weeks off, plus elranatamab injections twice a month.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cemsidomide (oral drug) and elranatamab (injectable antibody)
What this could lead to: If this works, it could offer a new treatment option for people with multiple myeloma that has come back after other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 60 people. The main goal is safety, not proof of effectiveness. Side effects or lack of response are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Baylor University Medical Center
NOT_YET_RECRUITING

Dallas, Texas, 75246, United States
Dartmouth-Hitchcock Medical Center
NOT_YET_RECRUITING

Lebanon, New Hampshire, 03756, United States
Duke Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Houston Methodist Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Huntsman Cancer Institute, University of Utah
NOT_YET_RECRUITING

Salt Lake City, Utah, 84112, United States
Indiana University
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
Loyola University Medical Center
NOT_YET_RECRUITING

Maywood, Illinois, 60153, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Norton Cancer Institute St. Matthews
RECRUITING

Louisville, Kentucky, 40207, United States
Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
Perlmutter Cancer Center at NYU Langone Hospital
RECRUITING

Brooklyn, New York, 11203, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
UC Davis Comprehensive Cancer Center
NOT_YET_RECRUITING

Sacramento, California, 95817, United States
UCLA Health, Jonsson Comprehensive Cancer Center
NOT_YET_RECRUITING

Santa Monica, California, 90404, United States
University of Florida
NOT_YET_RECRUITING

Gainesville, Florida, 32610, United States
University of Maryland Greenbaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
University of Miami
NOT_YET_RECRUITING

Miami, Florida, 33136, United States
University of Nebraska
NOT_YET_RECRUITING

Omaha, Nebraska, 68105, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.